Charles River Laboratories International (NYSE:CRL) Updates FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 9.100-9.600 for the period, compared to the consensus earnings per share estimate of 9.600. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CRL. TD Cowen raised their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Morgan Stanley lowered their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Finally, StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $197.64.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $154.63 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a 50-day moving average of $174.59 and a 200-day moving average of $189.16. The company has a market cap of $7.91 billion, a PE ratio of 19.35, a P/E/G ratio of 5.91 and a beta of 1.37. Charles River Laboratories International has a one year low of $150.79 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. On average, equities research analysts predict that Charles River Laboratories International will post 10.16 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).